Skip to main content
Celon Pharma S.A. logo

Celon Pharma S.A. — Investor Relations & Filings

Ticker · CLN ISIN · PLCLNPH00015 LEI · 259400Q0ERJT0NC5DT24 WAR Manufacturing
Open in API
Filings indexed 709 across all filing types
Latest filing 2021-03-31 Board/Management Inform…
Country PL Poland
Listing WAR CLN

About Celon Pharma S.A.

https://celonpharma.com/en/

Celon Pharma S.A. is an integrated pharmaceutical company that conducts advanced research and manufactures modern drugs. The company is engaged in the development, production, distribution, and marketing of therapeutic solutions. Its primary focus is on developing treatments for cancers, neurological diseases, diabetes, and other metabolic disorders. As a marketing authorization holder, Celon Pharma manages the full product lifecycle, from scientific research and development to commercialization, aiming to improve patient health and quality of life.

Recent filings

Filing Released Lang Actions
Oswiadczenie_zarzadu_w_sprawie_firmy_audytorskiej.pdf
Board/Management Information Classification · 1% confidence The document is titled "Informacja Zarządu Celon Pharma S.A. w sprawie wyboru firmy audytorskiej" (Information of the Management Board of Celon Pharma S.A. regarding the selection of the audit firm). It explicitly discusses the selection process, compliance with regulations, and the independence of the audit firm responsible for examining the financial statements for the fiscal year 2020. This content directly relates to the audit process and the resulting report's integrity, fitting the definition of an Audit Report / Information (AR), which covers applied accounting principles and audit results, even if this specific document is the management's confirmation of the auditor's suitability rather than the final audit opinion itself. It is not a full Annual Report (10-K) or a mere announcement of a report (RPA).
2021-03-31 Polish
Oswiadczenie_zarzadu_o_rzetelnosci_sprawozdan.pdf
Management Reports Classification · 1% confidence The document text is very short (778 characters) and appears to be a formal declaration from the Management Board ('Oświadczenie Zarządu') regarding the fairness and accuracy of the annual financial statements ('roczne sprawozdanie finansowe') and the management report for the fiscal year 2020. This type of statement is a mandatory component often found within a larger Annual Report (10-K) or an Audit Report (AR). However, since the text itself is only the declaration and not the full financial statements or the audit opinion, and given the context of Polish regulatory filings, this specific declaration strongly relates to the integrity of the financial reporting process. It is most closely aligned with the content covered in an Audit Report/Information (AR) or potentially a component of the Annual Report (10-K). Given the focus is solely on the management's assertion about the accuracy of the financial statements, 'Audit Report / Information' (AR) is the most appropriate classification for this specific declaration snippet, as it pertains directly to the assurance/verification aspect of the annual results, even if it's the management's part of that assurance process. It is not a general announcement of a report (RPA) because it contains substantive content (the declaration itself).
2021-03-31 Polish
Sprawozdanie z badania
Audit Report / Information Classification · 1% confidence The document is titled "Sprawozdanie niezależnego biegłego rewidenta z badania" (Independent Auditor's Report on the Audit) and specifically mentions "Sprawozdanie z badania rocznego sprawozdania finansowego" (Report on the audit of the annual financial statements). It contains the auditor's opinion, details about the scope of the audit (including balance sheet, income statement, cash flow statement for the year ended December 31, 2020), materiality thresholds, and key audit matters. This content is characteristic of an Audit Report, which aligns with the definition for Code AR (Audit Report / Information), even though it relates to the annual financial statements. Since the document *is* the auditor's opinion/report and not the full Annual Report (10-K) or just an announcement of a report (RPA), AR is the most precise fit among the provided options for a standalone audit opinion. FY 2020
2021-03-31 Polish
Podpisanie umowy z NCBR o dofinansowanie projektu dotyczącego kandydata na lek inhalacyjny w terapii chorób płuc o podłożu zapalnym i fibrotycznym w tym powikłań COVID-19 - Content (PL)
Regulatory Filings Classification · 1% confidence The document is a brief announcement (973 characters) referencing a previous current report (raport bieżący nr 7/2021) regarding the signing of a co-financing agreement for a project with the National Centre for Research and Development (NCBR). It details the total cost (46.9 million PLN) and the grant amount (27.2 million PLN). Since this is a short announcement informing the market about a specific event (signing of a financing agreement) and referencing prior disclosures, it fits best under Capital/Financing Update (CAP) or potentially a general Regulatory Filing (RNS). Given the specific nature of receiving significant funding/grant money, CAP is the most precise fit, as it relates directly to capital structure/financing activities, even if it's grant-based funding for a project.
2021-03-31 Polish
Otrzymanie zawiadomienia o zmianie stanu posiadania akcji Spółki - Content (PL)
Major Shareholding Notification Classification · 1% confidence The document is a formal notification from Generali Powszechne Towarzystwo Emerytalne S.A. to Celon Pharma S.A. regarding a change in the percentage of voting rights held by Generali's Fund. Specifically, the notification states that the Fund's share of votes decreased below the 5% threshold, referencing Polish securities law (art.69 Ustawy o ofercie publicznej). This type of filing details transactions by significant shareholders or insiders that cross regulatory thresholds. Based on the definitions, this clearly falls under 'Major Shareholding Notification' (MRQ), which covers changes in significant share ownership levels crossing thresholds.
2021-03-26 Polish
Podpisanie umowy z NCBR o dofinansowanie projektu dotyczącego rozwoju terapeutyku opartego o agonizm receptorów GPR40 w terapii bólu neuropatycznego - Content (PL)
Capital/Financing Update Classification · 1% confidence The document is a brief announcement (936 characters) referencing a previous current report (raport bieżący) and detailing the signing of a co-financing agreement with the National Centre for Research and Development (NCBR) for a specific project. It provides key financial figures (total cost and grant amount) and the project end date. This is not a full financial report (like 10-K or IR), nor is it a standard earnings release (ER) or a management discussion (MDA). It specifically concerns funding and capital structure changes related to a project grant. This fits best under 'Capital/Financing Update' (CAP), as it announces the securing of significant external funding/grant money.
2021-03-24 Polish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.